Olaratumab (Lartruvo)

BNF:

not listed

Status:

Red

Decision Date:

September 2017

Comments

RED^1,2,3:NICE TA465 - olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma. This guidance has been withdrawn because olaratumumab (Lartruvo) no longer has a marketing authorisation. See MHRA guidance for further details

NHSE is the responsible commissioner for this drug and it is available via the Cancer Drug Fund.

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again